Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma
Canadian Cancer Trials Group
Canadian Cancer Trials Group
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Sumitomo Pharma America, Inc.
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
National Institutes of Health Clinical Center (CC)
University of Athens
AIDS Malignancy Consortium
Jonsson Comprehensive Cancer Center
University of Arizona
M.D. Anderson Cancer Center
Swiss Cancer Institute
Memorial Sloan Kettering Cancer Center
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Virginia Commonwealth University
SWOG Cancer Research Network
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
University of Kansas Medical Center
UNC Lineberger Comprehensive Cancer Center
Emory University
SCRI Development Innovations, LLC
University of Rochester
French Innovative Leukemia Organisation
M.D. Anderson Cancer Center
Kantonsspital Aarau
University Hospital Plymouth NHS Trust
Augusta University
Amgen
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
City of Hope Medical Center
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
NYU Langone Health
Jonsson Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Mayo Clinic
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Millennium Pharmaceuticals, Inc.